NSE மற்றும் BSE-யின் ஒவ்வொரு கார்ப்பரேட் அறிவிப்பும், AI-யால் சில நிமிடங்களில் படிக்கப்பட்டு விளக்கப்படுகிறது — தாக்கம், முக்கிய புள்ளிவிவரங்கள், குறுகிய/நீண்டகாலப் பார்வை, கவனிக்க வேண்டியவை.
குறிப்பு: இவை NSE பொது அறிக்கைகளின் AI-உருவாக்கிய, கல்வி நோக்கச் சுருக்கங்கள் — ஒவ்வொரு ஆவணத்தையும் ஆதாரமாகக் கொண்டவை, ஆனால் முதலீட்டு ஆலோசனை அல்ல, மேலும் முழுமையற்றதாகவும் இருக்கலாம். அசல் அறிக்கையுடன் சரிபார்க்கவும், செயல்படுவதற்கு முன் SEBI-பதிவு பெற்ற முதலீட்டு ஆலோசகரை அணுகவும்.
Krsnaa Diagnostics Seeks Approval for Director Appointments and ₹50 Lakh Remuneration Cap
Krsnaa Diagnostics has issued a postal ballot notice to seek shareholder approval for the re-appointment of Mr. Chetan Desai for a second 5-year term and the appointment of two new Independent Directors for 2-year terms. The company is also proposing a new remuneration structure for Independent Directors, involving a commission of up to 1% of net profits, capped at a maximum of ₹50 lakhs annually starting FY 2026-27. The e-voting process is scheduled to take place between June 05 and July 04, 2026, following the cut-off date of May 29, 2026.
முக்கிய அம்சங்கள்
Re-appointment of Mr. Chetan Desai as Independent Director for a 5-year term ending April 2031.Appointment of Mr. Raju Venkatraman and Ms. Lilian Jessie Paul as Independent Directors for 2-year terms.Proposed commission for Independent Directors capped at 1% of net profits or a maximum of ₹50,00,000 per year.E-voting period set from June 05, 2026, to July 04, 2026.Resolutions include approval for Mr. Chetan Desai to continue directorship beyond the age of 75 years.
👀 கவனிக்க வேண்டியவை
Investors should review the profiles of the new director appointees and ensure the proposed commission-based remuneration is aligned with the company's long-term profitability and governance standards.
Krsnaa Diagnostics FY26 PAT Hits ₹101 Cr; Q4 PAT Surges 101% YoY with Improved Receivables
Krsnaa Diagnostics reported a resilient FY26 with total revenue of ₹7,728 million and an EBITDA of ₹2,149 million (28% margin). The company achieved a significant milestone in Q4 FY26 with PAT growing 101% YoY to ₹417 million, supported by the highest quarterly collection in its history at ₹1,580 million. Management highlighted a reduction in Days Sales Outstanding (DSO) from 155 to 139 days, addressing historical concerns regarding working capital. With a ₹5,000 million capex deployment, the company claims a long-term revenue visibility of ₹6,000 to ₹7,000 crores over the next 5-7 years.
முக்கிய அம்சங்கள்
FY26 Revenue stood at ₹7,728 million with a 12% 5-year CAGR, outperforming the industry average of 8%.Q4 PAT grew by 101% YoY to ₹417 million, while Q4 EBITDA margins remained strong at 29%.DSO improved significantly to 139 days from 155 days in Q3, reflecting tighter working capital management.Retail diagnostics now contributes 8% of total revenue, with a network of 3,500+ touchpoints across 5 states.The company is deploying ₹5,000 million in capex, primarily for Rajasthan expansion and CT/MRI centers, targeting 200+ centers.
👀 கவனிக்க வேண்டியவை
Investors should view the improvement in DSO and record collections as a major positive for the PPP-heavy model. Monitor the scale-up of the Rajasthan project and the retail segment's progress toward double-digit contribution for margin expansion.
Krsnaa Diagnostics Q4 FY26 PAT Doubles to ₹417 Mn; Retail Revenue Surges 147% YoY
Krsnaa Diagnostics reported a steady 4% YoY revenue growth in Q4 FY26, reaching ₹1,926 million, while PAT surged 102% to ₹417 million, significantly aided by a ₹221.75 million fair valuation gain. The company's retail segment showed exceptional momentum, with revenue increasing 147% YoY to ₹158 million and its contribution to total revenue rising from 3% to 8%. For the full year FY26, revenue grew 8% to ₹7,728 million with EBITDA margins improving to 28%. The company continues to leverage its PPP infrastructure to scale its retail presence while maintaining a massive 70-95% price advantage over competitors.
முக்கிய அம்சங்கள்
Q4 FY26 PAT grew 102% YoY to ₹417 million, including a ₹221.75 million fair valuation gain from investment in Apulki Healthcare.Retail segment revenue jumped 147% YoY to ₹158 million, with patient count increasing from 0.09 million to 0.15 million.Full-year FY26 EBITDA stood at ₹2,149 million (up 10% YoY) with margins expanding by 69 bps to 28%.Network expanded to 190 CT/MRI centers and 4,700+ collection centers, serving 19.8 million patients in FY26.Maintains extreme cost leadership with tests like Vitamin B12 priced at ₹69, approximately 95% lower than market competitors.
👀 கவனிக்க வேண்டியவை
Investors should focus on the rapid scaling of the high-margin retail segment and the execution of the Rajasthan pathology project. While the PAT jump includes one-off gains, the underlying operational efficiency and retail pivot provide a strong long-term growth narrative.
Krsnaa Diagnostics to Host Q4 & FY26 Post Earnings Conference Call on May 26, 2026
Krsnaa Diagnostics Limited has scheduled its post-earnings conference call for Tuesday, May 26, 2026, at 12:30 PM IST. The management will discuss the financial performance for the quarter and full year ended March 31, 2026. The session will include a presentation followed by an interactive Q&A for analysts and institutional investors. Transcripts and audio recordings will be published on the company's website subsequently.
முக்கிய அம்சங்கள்
Conference call scheduled for May 26, 2026, at 12:30 Hrs IST.Discussion to cover financial results for the quarter and year ended March 31, 2026.Management will conduct an interactive Question and Answer session following the results briefing.Audio recordings and transcripts will be accessible on the company's official website.
👀 கவனிக்க வேண்டியவை
Investors should monitor the call for management commentary on margin sustainability and the status of new PPP (Public-Private Partnership) project executions.
Krsnaa Diagnostics Receives Income Tax Demand Notices Totaling ₹11.31 Crore
Krsnaa Diagnostics has been served with income tax demand notices for the assessment years 2018-19 and 2019-20, amounting to a total of ₹11.31 crore including interest. These orders follow a search operation conducted by the Income Tax Department in July 2022. The company has already challenged these assessment orders before appellate and judicial forums, expressing confidence in its legal position. While the amount is currently treated as a contingent liability, the company will evaluate the need for provisioning under Ind AS 37.
முக்கிய அம்சங்கள்
Total income tax demand of ₹11,30,54,699 raised for two assessment years.Specific demands include ₹4.04 crore for AY 2018-19 and ₹7.27 crore for AY 2019-20.The company has already initiated legal appeals and is contesting the orders on merit.Management confirms no operational disruption despite the ongoing tax litigation.The disclosure was delayed due to an internal compliance review after external consultants handled the initial litigation.
👀 கவனிக்க வேண்டியவை
Investors should monitor the outcome of the appellate proceedings as a final adverse ruling would impact the company's cash reserves and net profit. The ₹11.31 crore demand is significant but manageable for a company of this scale, provided no further liabilities arise from other assessment years.
📊 கடந்த 7 நாட்கள் — உணர்வு அடிப்படையில் பகுப்பாய்வு செய்யப்பட்ட அறிவிப்புகள்
Krsnaa Diagnostics Appoints Interim CFO and Overhauls Board with New Independent Directors
Krsnaa Diagnostics has announced a major leadership reshuffle, including the appointment of Mr. Chandra Prakash Singh as Interim CFO effective April 17, 2026. The board is adding significant expertise with new Independent Directors Raju Venkatraman (ex-Medall Healthcare) and Lilian Jessie Paul (PB Fintech board member) for two-year terms. These changes coincide with the departure of Whole-time Director Ms. Pallavi Bhatevara and two other directors as their tenures conclude in April 2026. The company has also reconstituted all major board committees, including Audit and Risk Management, to align with the new leadership structure.
முக்கிய அம்சங்கள்
Mr. Chandra Prakash Singh appointed as Interim CFO effective April 17, 2026, bringing 28 years of finance and IPO experience.New Independent Directors Raju Venkatraman and Lilian Jessie Paul join for 2-year terms starting April 25, 2026.Whole-time Director Ms. Pallavi Bhatevara and two Independent Directors to exit upon tenure completion in April 2026.Mr. Chetan Desai re-appointed as Independent Director for a subsequent 5-year term until April 2031.Complete reconstitution of Audit, NRC, CSR, Stakeholders, and Risk Management committees effective April 25, 2026.
👀 கவனிக்க வேண்டியவை
Investors should monitor the transition to a permanent CFO and observe if the new board composition leads to any shifts in strategic direction or operational efficiency.
Krsnaa Diagnostics Shareholders Approve Re-appointment of Executive Chairman for 5 Years
Krsnaa Diagnostics Limited has announced the successful passing of a postal ballot resolution for the re-appointment of Mr. Rajendra Khivraj Mutha as Executive Chairman. The resolution received overwhelming support, with 99.9951% of votes cast in favor of the 5-year term. This move ensures leadership continuity and stability for the diagnostic services provider. The voting process concluded on April 16, 2026, with negligible opposition from shareholders, indicating strong institutional and retail confidence in the current leadership.
முக்கிய அம்சங்கள்
Mr. Rajendra Khivraj Mutha re-appointed as Executive Chairman for a five-year tenureResolution passed with 19,451,298 votes in favor, representing 99.9951% of total valid votesOpposition was minimal, with only 952 votes (0.0049%) cast against the resolutionThe voting results were verified by Scrutinizer Dinesh Shivnarayan Birla and reported on April 16, 2026
👀 கவனிக்க வேண்டியவை
The high approval rating reflects strong shareholder trust in the existing management. Investors should view this as a sign of leadership stability and continuity in the company's strategic direction.
Krsnaa Diagnostics Allots INR 430 Crore NCDs to Asian Development Bank
Krsnaa Diagnostics has successfully allotted 43,000 Non-Convertible Debentures (NCDs) worth INR 430 crore to the Asian Development Bank (ADB) on a private placement basis. These unlisted, secured NCDs carry a coupon rate of 7.790% per annum with a tenure of seven years. The repayment is structured in 13 equal half-yearly installments starting six months from the allotment date. This significant capital infusion from a prestigious multilateral institution like ADB provides the company with long-term growth capital at a competitive interest rate.
முக்கிய அம்சங்கள்
Allotment of INR 430 crore worth of NCDs to Asian Development Bank (ADB)Fixed interest rate of 7.790% per annum payable half-yearlyLong-term tenure of 7 years with final maturity on February 23, 2033Repayment via 13 equal installments commencing 6 months from allotmentNCDs are secured against identified assets of the company
👀 கவனிக்க வேண்டியவை
Investors should view this as a strong validation of the company's business model by a global institution. The long-term funding at a sub-8% rate is favorable for expansion; monitor the deployment of these funds into high-RoE diagnostic projects.
Krsnaa Diagnostics Re-appoints Rajendra Mutha as Executive Chairman for 5-Year Term
The Board of Krsnaa Diagnostics has approved the re-appointment of Mr. Rajendra Mutha as Executive Chairman for a second five-year term. This new term will commence on April 26, 2026, and extend until April 25, 2031, ensuring leadership continuity for the company. Mr. Mutha brings over 20 years of experience in the pharmacy and diagnostics sectors to the role. The re-appointment is subject to shareholder approval via a postal ballot process.
முக்கிய அம்சங்கள்
Re-appointment of Mr. Rajendra Mutha as Executive Chairman for a 5-year termNew term effective from April 26, 2026, to April 25, 2031Mr. Mutha possesses over 20 years of specialized expertise in pharmacy and diagnosticsDecision is subject to final approval by shareholders through a postal ballotBoard meeting concluded at 21:10 Hrs on February 22, 2026
👀 கவனிக்க வேண்டியவை
Investors should view this as a positive sign of leadership stability and continuity in strategic direction. No immediate action is required as this is a routine re-appointment of a key founder-leader.
Krsnaa Diagnostics Q3 FY26 Revenue Up 4% to ₹181 Cr; Recovers ₹130 Cr in Pending Dues
Krsnaa Diagnostics reported a modest 4% YoY revenue growth to ₹1,812 million in Q3 FY26, impacted by seasonal factors and strategic operational pauses to recover government receivables. The company successfully recovered over ₹130 crores during the quarter, significantly improving its cash position and working capital discipline. The B2C segment showed strong momentum with an 8x YoY increase in retail revenue, while the company also expanded into tertiary care with its first PPP-based hospital in Pune. Despite margin pressure from expansion costs like the Rajasthan pathology rollout, management remains confident in the long-term scalability of the PPP model.
முக்கிய அம்சங்கள்
Revenue from operations stood at ₹1,812 million, representing a 4% year-on-year growth.Successfully recovered over ₹130 crores in long-pending government dues, strengthening the cash position.Retail (B2C) revenue grew 8x year-on-year, indicating successful diversification beyond PPP contracts.Network expanded to 190 CT/MRI centers and over 4,000 collection centers across 18 states and UTs.Launched India's first PPP-based cancer and cardiac care hospital in Pune under the Apulki brand.
👀 கவனிக்க வேண்டியவை
Investors should monitor the stabilization of margins as the Rajasthan pathology rollout matures and the B2C segment scales. The significant improvement in cash collections is a positive sign for working capital health, which has historically been a concern for PPP-heavy models.
Krsnaa Diagnostics Q3 FY26 Revenue Up 4%, Retail Business Grows 8x YoY
Krsnaa Diagnostics reported a 9% YoY increase in 9M FY26 revenue to ₹5,802 million, while Q3 FY26 revenue grew 4% to ₹1,812 million. A standout performer was the retail segment, which saw an 8-fold revenue jump to ₹177 million, now contributing 10% to the total group revenue compared to just 1% a year ago. The company maintained steady EBITDA margins at 28% for the nine-month period despite ongoing investments in the Rajasthan pathology project. Expansion remains a key focus with the launch of the first Apulki Healthcare Hospital and a significant increase in diagnostic touchpoints to 3,101.
முக்கிய அம்சங்கள்
9M FY26 Revenue grew 9% YoY to ₹5,802 mn with EBITDA margins improving by 92 bps to 28%.Retail segment revenue surged ~8x YoY to ₹177 mn, increasing its contribution to total revenue from 1% to 10%.Network expanded to 190 CT/MRI centres and 4,034 collection centres, maintaining a 75%+ bid win ratio in PPP projects.Operationalized the first Apulki Healthcare Hospital, a 150-bed PPP facility for cancer and cardiac care in Pune.Maintains a significant price advantage, offering services at 50-70% lower than market rates while sustaining industry-standard margins.
👀 கவனிக்க வேண்டியவை
Investors should focus on the rapid scaling of the retail business and the successful execution of the Rajasthan project as key growth drivers. The company's ability to maintain 28% EBITDA margins while offering disruptive pricing makes it a strong player in the affordable diagnostics space.
Krsnaa Diagnostics Q3 Revenue Up 4% YoY; Strong Cash Recovery of ₹130 Cr
Krsnaa Diagnostics reported a modest 4% YoY revenue growth to ₹1,812 mn for Q3 FY2026, while PAT declined by 21% YoY to ₹152 mn due to seasonal softness and front-loaded costs for the Rajasthan project. A significant highlight was the recovery of ₹130 crore in cash, primarily from government receivables, which significantly improves working capital efficiency. The company is also diversifying into tertiary care through Apulki Healthcare, launching a 150-bed hospital in Pune. Management expects the Rajasthan Pathology Project to drive significant revenue growth starting next fiscal year.
முக்கிய அம்சங்கள்
Q3 FY26 Revenue grew 4% YoY to ₹1,812 mn, while 9M FY26 Revenue rose 9% to ₹5,802 mn.PAT for the quarter decreased 21% YoY to ₹152 mn, impacted by seasonal factors and Rajasthan project readiness costs.Achieved significant cash recovery of over ₹130 crore during Q3, which is ₹100 crore higher YoY.Launched the first 150-bed PPP-based cancer and cardiac hospital in Pune under Apulki Healthcare.The Rajasthan Pathology Project is on track with meaningful revenue contribution expected from FY2027.
👀 கவனிக்க வேண்டியவை
Investors should monitor the execution of the Rajasthan project and the ramp-up of the new Apulki hospital venture as these are key growth drivers. The strong cash recovery addresses historical concerns regarding government receivables, making the long-term investment case more robust despite short-term margin pressure.
Krsnaa Diagnostics Q3 PAT Falls 23.6% YoY to ₹164.9 Mn; Revenue Down 3.5%
Krsnaa Diagnostics reported a weak set of standalone results for Q3 FY2026, with revenue declining 3.5% YoY to ₹1,594.32 million. Profit After Tax (PAT) saw a sharp decline of 23.6% YoY, falling to ₹164.92 million from ₹216.00 million in the previous year. On a sequential basis, the performance was even more subdued, with revenue and PAT dropping 12.8% and 29.0% respectively compared to Q2 FY2026. Furthermore, the company is currently litigating an Income Tax demand of ₹513.86 million across multiple assessment years.
முக்கிய அம்சங்கள்
Standalone Revenue from operations decreased by 3.5% YoY to ₹1,594.32 million in Q3 FY26.Standalone Profit After Tax (PAT) dropped significantly by 23.6% YoY to ₹164.92 million.Total expenses for the quarter stood at ₹1,420.05 million, leading to a contraction in profit margins compared to the previous year.The company is contesting an Income Tax demand of ₹513.86 million and has paid ₹102.77 million under protest.For the nine-month period ended Dec 31, 2025, revenue grew marginally by 2.1% YoY while PAT declined by 4%.
👀 கவனிக்க வேண்டியவை
Investors should exercise caution as the company shows signs of growth stagnation and margin pressure both on a YoY and QoQ basis. The ongoing tax dispute involving over ₹500 million remains a key monitorable risk factor.
Krsnaa Diagnostics CFO Pawan Daga Resigns After 5-Year Tenure
Krsnaa Diagnostics Limited has announced the resignation of Mr. Pawan Daga from the position of Chief Financial Officer, effective January 19, 2026. Mr. Daga served the company for five years, a period during which the management credits him for contributing to the firm's growth. The resignation is attributed to personal and professional priorities. The company must now identify a successor to lead its financial operations and maintain investor confidence.
முக்கிய அம்சங்கள்
Mr. Pawan Daga resigns as Chief Financial Officer (CFO) effective January 19, 2026The outgoing CFO completed a tenure of 5 years with the companyResignation cited as being due to personal and professional prioritiesAnnouncement made on January 15, 2026, providing a very short 4-day transition period
👀 கவனிக்க வேண்டியவை
Investors should monitor the company's upcoming announcements regarding the appointment of a new CFO to ensure leadership continuity. The short notice period between the announcement and the exit date is a point for cautious observation.
Krsnaa Diagnostics Limited's board approved the issuance of unlisted, secured, redeemable, transferable Non-Convertible Debentures (NCDs) for up to ₹430 crore via private placement. The company plans to issue 43,000 NCDs with a face value of ₹1,00,000 each. These NCDs have a tenure of 7 years from the allotment date and will be redeemed in 13 equal installments starting 6 months from allotment. The interest and principal will be payable on a half-yearly basis.
முக்கிய அம்சங்கள்
Issuance of Unlisted, Secured, Redeemable NCDs for up to ₹430 crore43,000 NCDs with a face value of ₹1,00,000 eachTenure of 7 years from the deemed date of allotmentRedemption in 13 equal installments commencing from 6 months from the allotment date
👀 கவனிக்க வேண்டியவை
Investors should monitor the terms of the NCD issuance and its impact on the company's debt levels. Review the company's future announcements regarding the allotment details and the specific assets charged as security.
Krsnaa Diagnostics Limited's board approved the issuance of unlisted, secured, redeemable, and transferable Non-Convertible Debentures (NCDs) for up to ₹430 crores via private placement. The company will issue 43,000 NCDs with a face value of ₹1,00,000 each. These NCDs have a tenure of 7 years from the allotment date. The principal will be redeemed in thirteen equal installments commencing 6 months from the allotment date, with interest and principal payable on a half-yearly basis.
முக்கிய அம்சங்கள்
Issuance of Unlisted, Secured NCDs up to ₹430 crore43,000 NCDs to be issued with a face value of ₹1,00,000 eachNCD tenure of 7 years from the deemed date of allotmentRedemption in 13 equal installments starting 6 months from allotmentInterest and principal payable on a half-yearly basis
👀 கவனிக்க வேண்டியவை
Investors should monitor the terms of the NCD issuance and its impact on the company's debt levels. Keep an eye on the interest rates and repayment schedule for these NCDs.
⚠️இந்தத் தளம் எவ்வாறு உருவாக்கப்படுகிறது: சந்தைத் தரவுப் பக்கங்கள் NSE/BSE வெளியீடுகள் மற்றும் நிறுவனங்களின் தாக்கல்களிலிருந்து தானாகக் கணக்கிடப்படுகின்றன; செய்திக் கட்டுரைகளும் அறிவிப்புப் பகுப்பாய்வுகளும் AI உதவியுடன் எழுதப்படுகின்றன, மனித மேற்பார்வையுடன்: AI உருவாக்குவதை எங்கள் ஆசிரியர்கள் மதிப்பாய்வு செய்கின்றனர். இரண்டிலும் பிழைகள் இருக்கலாம். எந்தவொரு முதலீட்டு முடிவுக்கு முன்பும் அசல் மூலங்களில் சரிபார்க்கவும். முதலீட்டு ஆலோசனை அல்ல; Flash Finance SEBI-பதிவு பெற்றது அல்ல. நாங்கள் AI-ஐ எவ்வாறு பயன்படுத்துகிறோம்
🎁 ஆரம்பகால ஆதரவாளர்களுக்கு மட்டும் · குறுகிய கால சலுகை
எங்கள் AI பங்குச் சந்தை பகுப்பாய்வு: டெலிகிராம், வாட்ஸ்அப்பில் இலவசம்
⚡ 3500+ நிறுவனங்களை நாங்கள் உடனுக்குடன் கண்காணிக்கிறோம். NSE-யில் ஒரு நிறுவன அறிவிப்பு வெளியானதுமே, எங்கள் AI அதைப் படித்து, சுருக்கி, அதன் தாக்கத்தைச் சில நொடிகளில் உங்களுக்குச் சொல்கிறது.
இதுபோன்ற AI பகுப்பாய்வுக்குக் கட்டணத் தளங்கள் ஆண்டுக்கு ₹1,00,000-க்கும் மேல் வசூலிக்கின்றன. எங்கள் சேனல்களில் இது இலவசம்.
